Ancylostomiasis medical therapy

	Ancylostomiasis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Ancylostomiasis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
Endoscopy
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Ancylostomiasis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Ancylostomiasis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Ancylostomiasis medical therapy
CDC on Ancylostomiasis medical therapy
Ancylostomiasis medical therapy in the news
Blogs on Ancylostomiasis medical therapy
Directions to Hospitals Treating Ancylostomiasis
Risk calculators and risk factors for Ancylostomiasis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

For stable uncomplicated cases
- Adult
  - Preferred regimen: Albendazole 400 mg PO single dose
  - Alternative regimen: Mebendazole 100 mg PO q12h for 3 days
  - Alternative regimen: Pyrantel Pamoate 11mg/kg PO q24h for 3 days (maximum, 1gm per dose)

↑ Loukas A, Hotez PJ, Diemert D, Yazdanbakhsh M, McCarthy JS, Correa-Oliveira R; et al. (2016). "Hookworm infection". Nat Rev Dis Primers. 2: 16088. doi:10.1038/nrdp.2016.88. PMID 27929101.